Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/301% below fair value
$9.61−0.62 (-6.06%)
Close on Nov 13, 2026Market cap $647.14MP/E –Yield –
Ginkgo Bioworks gross margin
Gross margin is gross profit as a percentage of revenue.
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 93.5% | +7.2 |
| Q2 FY2026 | Jun 30, 2026 | 91.5% | +2.2 |
| Q1 FY2026 | Mar 31, 2026 | 84.1% | – |
| Q3 FY2025 | Sep 30, 2025 | 84.3% | – |
| Q2 FY2025 | Jun 30, 2025 | 86.3% | – |
| Q1 FY2025 | Mar 31, 2025 | 89.3% | – |
See a number that looks wrong?